This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

225Ac/213Bi Generator

Alpha Emitter with small Penetration Range

225Ac and 213Bi are considered as the favorable radionuclide pair for the next generation of Targeted Radionuclide Therapy.

State of the art radionuclides for research on cancer treatments are currently medium range beta emitters such as 177Lu. With the increase of specific activity, for example achieved by the development of n.c.a. 177Lu, therapeutic doses could be delivered not only to the primary tumor, but also to small metastases.

Nevertheless, micrometastases or single cell diseases like leukemia can still not be reached effectively.

For these kinds of cancers, alpha emitting radionuclides such as 213Bi or 225Ac would be the favorable choice. Due to the small penetration range of alpha particles in tissue and their high linear energy transfer (LET) they promise a superior ratio between penetration of cancer cells and protection of healthy tissue.

Key Advantages

  • High elution yield (> 90 % of the loaded 225Ac activity)
  • Small elution volume (full elution in less than 1 ml)
  • Nontoxic eluent (0.1 M HCl/0.1 M NaI) – eluate can directly be used for labeling
  • Low breakthrough of 225Ac into 213Bi fraction


This product is for laboratory research purposes only